PMID- 19252096
OWN - NLM
STAT- MEDLINE
DCOM- 20090619
LR  - 20220224
IS  - 0363-6135 (Print)
IS  - 1522-1539 (Electronic)
IS  - 0363-6135 (Linking)
VI  - 296
IP  - 5
DP  - 2009 May
TI  - Release of proinflammatory mediators and expression of proinflammatory adhesion 
      molecules by endothelial progenitor cells.
PG  - H1675-82
LID - 10.1152/ajpheart.00665.2008 [doi]
AB  - Cell therapy with endothelial progenitor cells (EPCs) is an emerging therapeutic 
      option to promote angiogenesis or endothelial repair. Although the release of 
      angiogenic paracrine factors is known to contribute to their therapeutic effect, 
      little is known about their release of proinflammatory factors and expression of 
      proinflammatory adhesion molecules. "Early" EPCs and "late" EPCs were isolated 
      from human peripheral blood and their release of chemokines and 
      thromboinflammatory mediators as well as their expression of the proinflammatory 
      adhesion molecules was assessed at baseline and with stimulation. The effect of 
      simvastatin on monocyte chemoattractant protein-1 (MCP-1) secretion by late EPCs 
      from patients with vascular disease was also evaluated. All groups of EPCs 
      released chemokines and thromboinflammatory mediators. Early EPCs primarily 
      released thromboinflammatory mediators such as tissue factor (0.5 +/- 0.1 
      ng/million cells, P < 0.05), whereas adult late EPCs primarily released 
      chemokines such as MCP-1 (287 +/- 98 ng/million cells, P < 0.05). Stimulation 
      with tumor necrosis factor (TNF)-alpha augmented the expression of 
      proinflammatory adhesion molecules and paracrine factors by all EPC subtypes. The 
      release of MCP-1 by late EPCs was markedly reduced by simvastatin treatment of 
      the cells. All EPC subtypes expressed proinflammatory paracrine factors and 
      adhesion molecules involved in atherosclerosis. Future clinical studies should 
      therefore not only assess the efficacy of EPCs but also monitor inflammatory 
      activation following EPC transplantation in patients. Pharmacological modulation 
      of EPCs before and after transplantation may represent a novel approach to 
      improve their safety.
FAU - Zhang, Yanmin
AU  - Zhang Y
AD  - Univ. of Chicago, Pritzker School of Medicine, 5841 South Maryland Ave, Mail-Code 
      6080, Chicago, IL 60637, USA.
FAU - Ingram, David A
AU  - Ingram DA
FAU - Murphy, Michael P
AU  - Murphy MP
FAU - Saadatzadeh, M Reza
AU  - Saadatzadeh MR
FAU - Mead, Laura E
AU  - Mead LE
FAU - Prater, Daniel N
AU  - Prater DN
FAU - Rehman, Jalees
AU  - Rehman J
LA  - eng
GR  - K08 HL080082-04/HL/NHLBI NIH HHS/United States
GR  - K08 HL080082/HL/NHLBI NIH HHS/United States
GR  - K08 HL080082-01A1/HL/NHLBI NIH HHS/United States
GR  - K08 HL080082-03/HL/NHLBI NIH HHS/United States
GR  - K08 HL080082-02/HL/NHLBI NIH HHS/United States
GR  - K08-HL080082/HL/NHLBI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20090227
PL  - United States
TA  - Am J Physiol Heart Circ Physiol
JT  - American journal of physiology. Heart and circulatory physiology
JID - 100901228
RN  - 0 (CCL2 protein, human)
RN  - 0 (CCL5 protein, human)
RN  - 0 (CXCL8 protein, human)
RN  - 0 (Cell Adhesion Molecules)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokine CCL5)
RN  - 0 (Chemokines)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Interleukin-8)
RN  - 0 (Platelet Endothelial Cell Adhesion Molecule-1)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (Vascular Cell Adhesion Molecule-1)
RN  - 126547-89-5 (Intercellular Adhesion Molecule-1)
RN  - 9035-58-9 (Thromboplastin)
RN  - AGG2FN16EV (Simvastatin)
RN  - EC 3.1.3.48 (Leukocyte Common Antigens)
RN  - EC 3.1.3.48 (PTPRC protein, human)
SB  - IM
MH  - Adult
MH  - Adult Stem Cells/drug effects/*immunology
MH  - Cell Adhesion Molecules/*metabolism
MH  - Cell Proliferation
MH  - Cells, Cultured
MH  - Chemokine CCL2/metabolism
MH  - Chemokine CCL5/metabolism
MH  - Chemokines/*metabolism
MH  - Endothelial Cells/drug effects/*immunology
MH  - Fetal Stem Cells/drug effects/*immunology
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology
MH  - Inflammation Mediators/*metabolism
MH  - Intercellular Adhesion Molecule-1/metabolism
MH  - Interleukin-8/metabolism
MH  - Leukocyte Common Antigens/metabolism
MH  - *Paracrine Communication
MH  - Phenotype
MH  - Platelet Endothelial Cell Adhesion Molecule-1/metabolism
MH  - Simvastatin/pharmacology
MH  - Thromboplastin/metabolism
MH  - Tumor Necrosis Factor-alpha/metabolism
MH  - Vascular Cell Adhesion Molecule-1/metabolism
PMC - PMC2685352
EDAT- 2009/03/03 09:00
MHDA- 2009/06/20 09:00
PMCR- 2010/05/01
CRDT- 2009/03/03 09:00
PHST- 2009/03/03 09:00 [entrez]
PHST- 2009/03/03 09:00 [pubmed]
PHST- 2009/06/20 09:00 [medline]
PHST- 2010/05/01 00:00 [pmc-release]
AID - 00665.2008 [pii]
AID - H-00665-2008 [pii]
AID - 10.1152/ajpheart.00665.2008 [doi]
PST - ppublish
SO  - Am J Physiol Heart Circ Physiol. 2009 May;296(5):H1675-82. doi: 
      10.1152/ajpheart.00665.2008. Epub 2009 Feb 27.